uniQure N.V. Government Assistance Operating Income
uniQure N.V. (QURE) reported Government Assistance Operating Income of $5.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GovernmentAssistanceOperatingIncome · last filed 2026-03-02
- uniQure N.V. government assistance operating income for the quarter ending 2025-12-31 was $1.56M, a 5.35% decline year-over-year.
- uniQure N.V. government assistance operating income for the quarter ending 2025-09-30 was $1.01M, a 5.42% decline year-over-year.
- uniQure N.V. government assistance operating income for the quarter ending 2025-06-30 was $1.39M, a 16.25% decline year-over-year.
- uniQure N.V. government assistance operating income for the quarter ending 2025-03-31 was $1.72M, a 40.44% increase year-over-year.
- uniQure N.V. government assistance operating income for fiscal 2025 was $5.68M, a 1.41% increase from fiscal 2024.
- uniQure N.V. government assistance operating income for fiscal 2024 was $5.60M, a 5.84% increase from fiscal 2023.
- uniQure N.V. government assistance operating income for fiscal 2023 was $5.29M, a 13.00% decline from fiscal 2022.
- uniQure N.V. government assistance operating income for fiscal 2022 was $6.08M.
| Period end | Government Assistance Operating Income 3 month | Government Assistance Operating Income 6 month | Government Assistance Operating Income 9 month | Government Assistance Operating Income 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.57M derived: sum of 2 quarters · filed 2026-03-02 | $3.96M derived: sum of 3 quarters · filed 2026-03-02 | $5.68M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.01M 10-Q · filed 2025-11-10 | $2.40M derived: sum of 2 quarters · filed 2025-11-10 | $4.12M 10-Q · filed 2025-11-10 | $5.77M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $1.39M 10-Q · filed 2025-07-29 | $3.11M 10-Q · filed 2025-07-29 | $4.76M derived: sum of 3 quarters · filed 2026-03-02 | $5.83M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $1.72M 10-Q · filed 2025-05-09 | $3.36M derived: sum of 2 quarters · filed 2026-03-02 | $4.43M derived: sum of 3 quarters · filed 2026-03-02 | $6.10M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.72M derived: sum of 2 quarters · filed 2026-03-02 | $4.38M derived: sum of 3 quarters · filed 2026-03-02 | $5.60M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.07M 10-Q · filed 2025-11-10 | $2.73M derived: sum of 2 quarters · filed 2025-11-10 | $3.96M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.66M 10-Q · filed 2025-07-29 | $2.89M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $1.22M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $5.29M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $6.08M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |